Gastric Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GST027 MIFTS: 54	Gastric Lymphoma Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Gastric Lymphoma

MalaCards integrated aliases for Gastric Lymphoma:

Name: Gastric Lymphoma ¹² ⁷⁷ ⁵⁴ ³⁰ ⁵⁶ ¹⁵ ⁷⁴

Familial Primary Gastric Lymphoma ⁵⁴ ⁴⁵ ⁷⁴

Primary Gastric Lymphoma ⁵⁴

Lymphoma of the Stomach ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Gastrointestinal diseases Immune diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:10540

MeSH ⁴⁵ C535648

NCIt ⁵¹ C4636

UMLS ⁷⁴ C0349532 C1850900

Sources

Summaries for Gastric Lymphoma

MalaCards based summary : Gastric Lymphoma, also known as familial primary gastric lymphoma, is related to lymphoma, mucosa-associated lymphoid type and lymphoma. An important gene associated with Gastric Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Regulation of TP53 Activity. The drugs Amoxicillin and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : ⁷⁷ Primary gastric lymphoma (lymphoma that originates in the stomach itself) is an uncommon condition,... more...

Sources

Related Diseases for Gastric Lymphoma

Diseases related to Gastric Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)

#	Related Disease	Score	Top Affiliating Genes
1	lymphoma, mucosa-associated lymphoid type	32.1	ATP12A BCL10 BCL2 BCL6
2	lymphoma	30.7	BAX BCL10 BCL2 BCL6
3	follicular lymphoma	29.9	BCL10 BCL2 BCL6
4	diffuse large b-cell lymphoma	29.6	BCL10 BCL6 TP53
5	burkitt lymphoma	29.5	BAX BCL2 BCL6
6	acquired immunodeficiency syndrome	29.5	ALB BCL6 TP53
7	mantle cell lymphoma	29.4	BCL2 BCL6 TP53
8	marginal zone b-cell lymphoma	29.3	BCL10 BCL2 BCL6
9	gastric adenocarcinoma	29.2	BAX BCL2 TP53 VEGFA
10	lymphoma, non-hodgkin, familial	29.2	BAX BCL10 BCL2 BCL6 TP53
11	b-cell lymphomas	28.8	BAX BCL10 BCL2 BCL6 TP53
12	lymphoma, gastric non hodgkins type	11.1
13	nodal marginal zone lymphoma	10.3
14	central nervous system lymphoma	10.3	BCL6 TP53
15	mature teratoma	10.3	PCNA TP53
16	oral leukoplakia	10.3	PCNA TP53
17	fibrillary astrocytoma	10.3	PCNA TP53
18	central nervous system hematologic cancer	10.2	BCL6 TP53
19	helicobacter pylori infection	10.2
20	adenocarcinoma	10.2
21	primary effusion lymphoma	10.2	BCL6 VEGFA
22	lipodermatosclerosis	10.2	PCNA VEGFA
23	acinar cell carcinoma	10.2	BCL10 TP53
24	rh isoimmunization	10.2	ALB BCL10
25	lymphoma, hodgkin, classic	10.2
26	ulcerative stomatitis	10.2	ALB TP53
27	severe nonproliferative diabetic retinopathy	10.2	ALB VEGFA
28	gastritis	10.1
29	esophagus adenocarcinoma	10.1	ATP12A TP53
30	capillary disease	10.1	ALB ATP12A
31	acroosteolysis	10.1	ALB VEGFA
32	drug allergy	10.1	ALB ATP12A
33	plasmablastic lymphoma	10.1
34	background diabetic retinopathy	10.1	ALB VEGFA
35	castleman disease	10.1	BCL6 VEGFA
36	inverted papilloma	10.1	PCNA TP53
37	hypertensive nephropathy	10.1	ALB VEGFA
38	polyposis, skin pigmentation, alopecia, and fingernail changes	10.1	ALB ATP12A
39	jejunoileitis	10.1	ALB ATP12A
40	esophageal varix	10.1	ALB ATP12A
41	juvenile nasopharyngeal angiofibroma	10.1	PCNA VEGFA
42	aspiration pneumonia	10.1	ALB ATP12A
43	primary peritoneal carcinoma	10.1	TP53 VEGFA
44	blind loop syndrome	10.1	ALB ATP12A
45	mature b-cell neoplasm	10.1	BCL6 TP53
46	peptic ulcer perforation	10.1	ALB ATP12A
47	high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement	10.1	BCL2 BCL6
48	fallopian tube carcinoma	10.1	TP53 VEGFA
49	gastric cancer	10.1
50	hydrops, lactic acidosis, and sideroblastic anemia	10.1	ALB VEGFA

Graphical network of the top 20 diseases related to Gastric Lymphoma:

Sources

Symptoms & Phenotypes for Gastric Lymphoma

GenomeRNAi Phenotypes related to Gastric Lymphoma according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.62	BAX BCL10 BCL2 PCNA TP53
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.62	BAX BCL10 BCL2 PCNA TP53
3	Increased viability with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.26	BAX BCL2 PCNA TP53

MGI Mouse Phenotypes related to Gastric Lymphoma:

⁴⁷ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.06	ALB BAX BCL10 BCL2 BCL6 PCNA
2	cellular	MP:0005384	10.04	ALB BAX BCL10 BCL2 BCL6 TP53
3	growth/size/body region	MP:0005378	9.98	ATP12A BAX BCL2 BCL6 PCNA TP53
4	hematopoietic system	MP:0005397	9.95	BAX BCL10 BCL2 BCL6 PCNA TP53
5	mortality/aging	MP:0010768	9.92	ALB BAX BCL10 BCL2 BCL6 PCNA
6	immune system	MP:0005387	9.91	BAX BCL10 BCL2 BCL6 PCNA TP53
7	digestive/alimentary	MP:0005381	9.88	ALB ATP12A BCL2 TP53 VEGFA
8	muscle	MP:0005369	9.73	ALB BAX BCL2 BCL6 TP53 VEGFA
9	neoplasm	MP:0002006	9.55	ALB BAX BCL2 TP53 VEGFA
10	renal/urinary system	MP:0005367	9.43	ALB ATP12A BAX BCL2 TP53 VEGFA
11	reproductive system	MP:0005389	9.1	BAX BCL2 BCL6 PCNA TP53 VEGFA

Sources

Drugs & Therapeutics for Gastric Lymphoma

Drugs for Gastric Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Amoxicillin

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

26787-78-0

33613

Metronidazole

Approved

Phase 4,Phase 3,Phase 2

443-48-1

4173

Clarithromycin

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

81103-11-9

84029

Lansoprazole

Approved, Investigational

Phase 4

103577-45-3

3883

Dexlansoprazole

Approved, Investigational

Phase 4

138530-94-6, 103577-45-3

9578005

Rabeprazole

Approved, Investigational

Phase 4

117976-89-3

5029

Doxycycline

Approved, Investigational, Vet_approved

Phase 4,Phase 2

564-25-0

54671203

Esomeprazole

Approved, Investigational

Phase 4

161796-78-7, 119141-88-7, 161973-10-0

9568614 4594

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Anti-Ulcer Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Antiparasitic Agents

Phase 4,Phase 3,Phase 2

Antacids

Phase 4,Phase 3,Phase 2,Not Applicable

Antiprotozoal Agents

Phase 4,Phase 3,Phase 2

Gastrointestinal Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Proton Pump Inhibitors

Phase 4,Phase 3,Phase 2,Not Applicable

Cytochrome P-450 CYP3A Inhibitors

Phase 4,Phase 3,Phase 2,Not Applicable

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 3,Phase 2,Not Applicable

Antibiotics, Antitubercular

Phase 4,Phase 2,Not Applicable

Antimalarials

Phase 4,Phase 2

Renal Agents

Phase 4

Pharmaceutical Solutions

Phase 4

Topoisomerase Inhibitors

Phase 4

Anti-Infective Agents, Urinary

Phase 4

Cytochrome P-450 CYP1A2 Inhibitors

Phase 4

Chlorambucil

Approved

Phase 3,Phase 2

305-03-3

2708

Tinidazole

Approved, Investigational

Phase 3

19387-91-8

5479

Omeprazole

Approved, Investigational, Vet_approved

Phase 3,Phase 2,Not Applicable

73590-58-6

4594

rituximab

Approved

Phase 3,Phase 2,Phase 1

174722-31-7

10201696

Antineoplastic Agents, Alkylating

Phase 3,Phase 2

Alkylating Agents

Phase 3,Phase 2

Antineoplastic Agents, Immunological

Phase 3,Phase 2,Phase 1

Immunologic Factors

Phase 3,Phase 2,Phase 1

Antirheumatic Agents

Phase 3,Phase 2

Lenalidomide

Approved

Phase 2

191732-72-6

216326

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

5743

Tetracycline

Approved, Vet_approved

Phase 2

60-54-8

5353990

Bismuth subsalicylate

Approved, Vet_approved

Phase 2

14882-18-9

53629521

Loperamide

Approved

Phase 2

53179-11-6

3955

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Cyclophosphamide

Approved, Investigational

Phase 2

6055-19-2, 50-18-0

2907

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Vincristine

Approved, Investigational

Phase 2

2068-78-2, 57-22-7

5978

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751

Vidarabine

Approved, Investigational

Phase 2

24356-66-9

21704 32326

Everolimus

Approved

Phase 2

159351-69-6

6442177 70789204

Interventional clinical trials:

(show all 45)

#	Name	Status	NCT ID	Phase	Drugs
1	Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection	Completed	NCT03524833	Phase 4	Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
2	Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection	Completed	NCT03521726	Phase 4	Amoxicillin;Rabeprazole, Amoxicillin
3	Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection	Completed	NCT03516669	Phase 4	Clarithromycin;Amoxicillin, Clarithromycin
4	Intraluminal Therapy for Helicobacter Pylori Infection	Completed	NCT03124420	Phase 4	Lansoprazole;Amoxicillin;Clarithromycin
5	High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection	Recruiting	NCT02553083	Phase 4	Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
6	Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution	Not yet recruiting	NCT03832465	Phase 4	Levofloxacin film-coated tablet;Levofloxacin intravenous solution
7	Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach	Unknown status	NCT00003617	Phase 3	chlorambucil;clarithromycin;omeprazole;tinidazole
8	Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation	Unknown status	NCT00154440	Phase 3	proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
9	Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma	Active, not recruiting	NCT00210353	Phase 3	chlorambucil (drug);rituximab+chlorambucil;rituximab
10	Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type	Unknown status	NCT00923663	Phase 2	Lenalidomide
11	Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas	Unknown status	NCT00783367	Phase 2	lenalidomide-low dose dexamethasone plus rituximab;Lenalidomide + Rituximab
12	Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma	Completed	NCT00003151	Phase 2	amoxicillin;clarithromycin;metronidazole hydrochloride;omeprazole;tetracycline hydrochloride
13	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	NCT00002682	Phase 2	Amoxicillin;Bismuth Subsalicylate;Clarithromycin;Metronidazole Hydrochloride;Omeprazole;Tetracycline Hydrochloride
14	Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma	Completed	NCT00204659	Phase 2	Rituximab + CHOP chemotherapy
15	Velcade in MALT Lymphoma Patients	Completed	NCT00373906	Phase 2	Bortezomib (Velcade)
16	Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients	Completed	NCT00373646	Phase 2	Thalidomide, Pharmion
17	Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma	Completed	NCT01015248	Phase 2	Rituximab and Bendamustine
18	VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy	Completed	NCT00210327	Phase 2	Bortezomib (drug)
19	Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma	Completed	NCT00117156	Phase 2	Fludarabine;Rituximab
20	Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue	Completed	NCT01611259	Phase 2	Rituximab and Lenalidomide
21	A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae	Completed	NCT01010295	Phase 2	doxycycline (tetracycline)
22	Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)	Completed	NCT01164267	Phase 2	Everolimus
23	Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma	Completed	NCT00656812	Phase 2	Rituximab;2-CdA
24	Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Completed	NCT00989586	Phase 1, Phase 2
25	A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma	Completed	NCT00081809	Phase 2	autologous human tumor-derived HSPPC-96
26	Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma	Recruiting	NCT03031483	Phase 2	clarithromycin and lenalidomide
27	Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma	Active, not recruiting	NCT01808599	Phase 2	Chlorambucil;Rituximab i.v.;Rituximab s.c.
28	R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)	Active, not recruiting	NCT01427114	Phase 2	rituximab, cyclophosphamide, vincristine, and prednisolone
29	Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma	Active, not recruiting	NCT00377195	Phase 2
30	Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma	Not yet recruiting	NCT03261349	Phase 2	Ledipasvir and sofosbuvir
31	VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy	Terminated	NCT00210392	Phase 2	Bortezomib (drug)
32	Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies	Recruiting	NCT02924402	Phase 1
33	Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.	Not yet recruiting	NCT03886649	Phase 1	Copanlisib;Venetoclax
34	Immediate Detection of Helicobacter Infection With a New Electrochemical System.	Unknown status	NCT01234389	Not Applicable
35	The Revolutions of Helicobacter Pylori Infection, Bacterial Density, and Histological Features After Antrectomy	Unknown status	NCT00441831
36	Reinfection After Eradication of Helicobacter Pylori Infection	Unknown status	NCT02674802
37	Endomicroscopy and Gastric MALT-lymphoma	Completed	NCT01583699	Not Applicable
38	Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori	Completed	NCT01264822		Rabeprazole Sodium
39	Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome	Completed	NCT00327132	Not Applicable	Omeprazole, Amoxicillin, Clarithromycin
40	Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma	Completed	NCT00201422	Not Applicable
41	Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"	Completed	NCT03219723		Vonoprazan;Amoxicillin hydrate;Clarithromycin;Metronidazole
42	Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia	Completed	NCT02520895
43	Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma	Recruiting	NCT02987127
44	Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma	Recruiting	NCT03680586	Not Applicable
45	Tumor Registry of Lymphatic Neoplasia	Active, not recruiting	NCT00889798

Search NIH Clinical Center for Gastric Lymphoma

Cochrane evidence based reviews: familial primary gastric lymphoma

Sources

Genetic Tests for Gastric Lymphoma

Genetic tests related to Gastric Lymphoma:

#	Genetic test	Affiliating Genes
1	Gastric Lymphoma ³⁰

Sources

Anatomical Context for Gastric Lymphoma

MalaCards organs/tissues related to Gastric Lymphoma:

⁴²

B Cells, T Cells, Liver, Kidney, Pancreas, Bone, Bone Marrow

Sources

Publications for Gastric Lymphoma

Articles related to Gastric Lymphoma:

(show top 50) (show all 441)

#	Title	Authors	Year
1	Gastric inflammatory fibroid polyp tumor with acute intestinal obstruction-Vanek's tumor can mimick a giant gastrointestinal stromal tumor or a gastric lymphoma. ( 29682464 )	Fleres F....Cucinotta E.	2018
2	Four-dimensional cone-beam computed tomography-guided radiotherapy for gastric lymphoma. ( 29086348 )	Toya R....Oya N.	2018
3	Primary Gastric Lymphoma: Clinicopathological Profile. ( 29963454 )	Malipatel R....Devarbhavi H.	2018
4	Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. ( 29779412 )	JuA!rez-Salcedo L.M....Dalia S.	2018
5	Diagnosis of Superficial Gastric Lesions Together with Six Gastric Lymphoma Cases via Probe-Based Confocal Laser Endomicroscopy: A Retrospective Observational Study. ( 30008745 )	Chen Q...Zhou Q	2018
6	Epstein-Barr virus-positive mucocutaneous ulcer colliding with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (malt lymphoma) that developed in the palatine tonsils of an immunocompetent patient after gastric lymphoma relapse. ( 30588472 )	Lee YM...Kim JM	2018
7	Severe upper gastrointestinal bleeding determined by a gastric lymphoma associated with Helicobacter pylori-positive atrophic gastritis. ( 28730251 )	ObleagA8 C.V....VArlcea I.D.	2017
8	Gastric Kaposi's sarcoma simulating gastric lymphoma during endoscopic ultrasound examination. ( 28685740 )	Okasha H.H....Baddour N.	2017
9	Isolated Pulmonary Valve Vegetations in a Patient with Gastric Lymphoma Diagnosed by Endoscopic Ultrasound. ( 29560679 )	Okasha H....El-Kafrawi A.	2017
10	Gastric lymphoma: association with Helicobacter pylori outer membrane protein Q (HopQ) and cytotoxic-pathogenicity activity island (CPAI) genes. ( 29143724 )	Yakoob J....Khan R.	2017
11	The Role of Endoscopic Ultrasound in the Diagnosis and Management of Primary Gastric Lymphoma. ( 28400819 )	Schizas D....Papanikolaou I.S.	2017
12	CT-based radiomics signature for differentiating Borrmann type IV gastric cancer from primary gastric lymphoma. ( 28629560 )	Ma Z....Liu Z.	2017
13	Multimodality Treatment of Gastric Lymphoma. ( 28325194 )	Ikoma N....Mansfield P.F.	2017
14	Clinical manifestations and endoscopic presentations of gastric lymphoma: a multicenter seven year retrospective survey. ( 28617031 )	Cui X....Gao Y.	2017
15	Diffuse large B cell gastric lymphoma a rare disease: the effort to obtain scientific data in a multicenter, multinational retrospective trial. ( 27521853 )	Hamerschlak N.	2016
16	Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma. ( 27482643 )	Hwang J.P....Lim S.M.	2016
17	The clinical characteristics of primary gastric lymphoma detected during screening for gastric cancer in Korea. ( 26850225 )	Yang H.J....Kim J.S.	2016
18	18F-FDG PET/CT Imaging of Primary Gastric Lymphoma. ( 27493260 )	Davis B.S....Wolin E.A.	2016
19	(18)F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma. ( 27678362 )	Li X.F....Xu W.G.	2016
20	4D-Listmode-PET-CT and 4D-CT for optimizing PTV margins in gastric lymphoma : Determination of intra- and interfractional gastric motion. ( 26902523 )	Reinartz G....Eich H.T.	2016
21	H. pylori-associated gastric lymphoma: Complete remission in an HIV-positive patient treated with HAART and H. pylori eradication therapy. ( 27206927 )	Verduzco-RodrA-guez L....Cruz Lara L.A.	2016
22	Clinical characteristics and prognostic factors of primary gastric lymphoma: A retrospective study with 165 cases. ( 27495029 )	Wang Y.G....Hu J.K.	2016
23	Indication for liver transplantation in a patient with a history of a gastric lymphoma. ( 26937630 )	Ruiz Pardo J....Parrilla Paricio P.	2016
24	High expression of PTPN21 in B-cell non-Hodgkin's gastric lymphoma, a positive mediator of STAT5 activity. ( 26771814 )	Plani-Lam J.H....Song Y.Q.	2016
25	Massive gastrointestinal bleeding after chemotherapy for gastric lymphoma. ( 26921535 )	Sousa M....Nunes V.	2016
26	Survival of patients with gastric lymphoma in Germany and in the United States. ( 25967274 )	Castro F.A....Brenner H.	2015
27	Colonic inflammation in a samoan immigrant with gastric lymphoma shown by positron emission tomography. ( 25948555 )	Burt A....Hoh C.	2015
28	Primary gastric lymphoma in a soldier presenting as acute gastrointestinal bleeding. ( 28265419 )	Ostfeld I....Moran-Gilad J.	2015
29	Refractory peptic ulceration following radiation therapy in primary gastric lymphoma: A report of two cases. ( 25435934 )	Zeng C....Chen Y.	2015
30	Spontaneous regression of high grade primary gastric Lymphoma in an untreated viral hepatitis infection. ( 24512317 )	Rojas-Hernandez C.M....Fekrazad M.H.	2014
31	Gastrocolic fistula secondary to primary gastric lymphoma. ( 24932326 )	Berri T.	2014
32	A retrospective study of feline gastric lymphoma in 16 chemotherapy-treated cats. ( 24216491 )	Gustafson T.L....Flory A.	2014
33	Radiotherapy for gastric lymphoma: a planning study of 3D conformal radiotherapy, the half-beam method, and intensity-modulated radiotherapy. ( 25161174 )	Inaba K....Itami J.	2014
34	Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology. ( 25258586 )	Mehmet K....Benekli M.	2014
35	(18)F-fluorodeoxyglucose positron emission tomography/computed tomography findings of gastric lymphoma: Comparisons with gastric cancer. ( 25202405 )	Wu J....Lu G.M.	2014
36	Clinicopathological characteristics and therapeutic outcomes of synchronous gastric adenocarcinoma and gastric lymphoma. ( 25202092 )	Namikawa T....Hanazaki K.	2014
37	The evolving role of surgery for gastric lymphoma: from curative resection to surgical management of complications. ( 25347493 )	Paulus E.M....Munene G.	2014
38	Malignant gastric lymphoma with spontaneous perforation. ( 23329705 )	Shimada S....Okamoto H.	2013
39	Hepatic dysfunction after radiotherapy for primary gastric lymphoma. ( 23283868 )	Tanaka H....Hoshi H.	2013
40	Primary Gastric Lymphoma Presenting as Acute Pancreatitis: A Case Report. ( 23846949 )	Raj M....Mohindra S.	2013
41	Clonal immunoglobulin heavy chain and T-cell receptor I^ gene rearrangements in primary gastric lymphoma. ( 24039368 )	Shan G.D....Xu G.Q.	2013
42	Primary submucosal nodular plasmacytoma of the stomach: a poorly recognized variant of gastric lymphoma. ( 23425357 )	Kanzawa M....Itoh T.	2013
43	Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment. ( 23043310 )	Sharma P....Kumar R.	2013
44	Predictive value of endoscopic ultrasound in diagnosis and staging of primary gastric lymphoma. ( 23837259 )	Vanis N....Dobrila-Dintinjana R.	2013
45	Unconvincing diagnosis of a rare subtype of primary gastric lymphoma with incongruent endoscopic presentation: a case of gastric schwannoma. ( 24365735 )	Lee S.S....Kim I.H.	2013
46	Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice? ( 22564515 )	Alevizos L....Zografos G.	2012
47	Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease. ( 22988526 )	SelAsukbiricik F....Ferhanoglu B.	2012
48	Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma. ( 21710234 )	Xie L....Yang J.L.	2012
49	A case of eosinophilic gastroenteritis mimicking gastric lymphoma associated with pancreatitis due to duodenal involvement. ( 23161306 )	A8aA9lar E....Dobrucali A.	2012
50	The diagnostic characteristics of a group of patients with primary gastric lymphoma: macroscopic, histopathological and immunohistochemical aspects. ( 22732804 )	Rotaru I....GA8man G.	2012

Sources

Genes for Gastric Lymphoma

Genes related to Gastric Lymphoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	BCL6	BCL6 Transcription Repressor	Protein Coding	29.17	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	11353050 16772602 9546062 (more) 18677925
2	BCL10	BCL10 Immune Signaling Adaptor	Protein Coding	26.47	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	11425462
3	TP53	Tumor Protein P53	Protein Coding	20.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	ALB	Albumin	Protein Coding	19.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	16.56	GeneCards inferred via : Publications (show sections)
6	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	16.21	GeneCards inferred via : Publications (show sections)
7	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	16.21	GeneCards inferred via : Publications (show sections)
8	BCL2	BCL2 Apoptosis Regulator	Protein Coding	16.21	GeneCards inferred via : Publications (show sections)
9	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	15.99	DISEASES inferred ¹⁵

Sources

Variations for Gastric Lymphoma

Sources

Expression for Gastric Lymphoma

Search GEO for disease gene expression data for Gastric Lymphoma.

Sources

Pathways for Gastric Lymphoma

Pathways related to Gastric Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)

#	Super pathways	Score	Top Affiliating Genes
1	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.82	BAX BCL2 TP53 VEGFA
2	Regulation of TP53 Activity ⁶⁷ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁷ Regulation of TP53 Activity through Methylation ⁶⁷ Regulation of TP53 Activity through Phosphorylation ⁶⁷ Transcriptional Regulation by TP53 ⁶⁷	12.8	BAX BCL6 PCNA TP53
3	TNFR1 Pathway ⁶⁵ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²³ Apoptosis through Death Receptors ⁶⁵ Apoptotic Pathways Triggered By HIV1 ⁶⁵ DR3 Signaling ⁶⁵ Fas Signaling ⁶⁵ GITR Pathway ⁶⁵ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁷ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁵ TRAIL Pathway ⁶⁵ TWEAK Pathway ⁶⁵	12.79	BAX BCL2 TP53 VEGFA
4	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	12.69	BAX BCL2 PCNA TP53 VEGFA
5	Pathways in cancer ³⁸	12.65	BAX BCL2 TP53 VEGFA
6	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.58	BAX BCL2 PCNA TP53 VEGFA
7	Chks in Checkpoint Regulation ⁶⁵ Show member pathways DNA Repair Mechanisms ⁶⁵ Estrogen-mediated S-Phase Entry ⁶⁵ G2-M Phase Transition ⁶⁵ Parkinson's Disease Pathway ⁶⁵ SREBP Proteolysis ⁶⁵	12.51	BAX BCL2 PCNA TP53
8	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.5	BAX BCL2 TP53 VEGFA
9	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.3	BAX BCL2 TP53
10	Development IGF-1 receptor signaling ²³ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²³ Signal transduction AKT signaling ²³	12.25	BAX PCNA TP53
11	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁸	12.24	BAX BCL2 TP53
12	Human T-cell leukemia virus 1 infection ³⁸	12.21	BAX PCNA TP53
13	Transcriptional misregulation in cancer ³⁸	12.11	BAX BCL6 TP53
14	Apoptosis and Autophagy ⁴	12.1	BAX BCL10 BCL2
15	p53 Signaling ⁶⁵ Show member pathways p53 Pathway ⁶⁸	12.09	BAX BCL2 TP53
16	Tuberculosis ³⁸	12.08	BAX BCL10 BCL2
17	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.06	BAX BCL2 TP53
18	Colorectal Cancer Metastasis ⁶⁵	12.02	BAX TP53 VEGFA
19	AKT Signaling Pathway ⁶⁸	11.99	BAX BCL2 TP53
20	Fluid shear stress and atherosclerosis ³⁸	11.93	BCL2 TP53 VEGFA
21	SMAD Signaling Network ⁶⁵	11.9	BCL2 TP53 VEGFA
22	Activation of BH3-only proteins ⁶⁷ Show member pathways Activation of BAD and translocation to mitochondria ⁶⁷ Activation of BIM and translocation to mitochondria ⁶⁷ Activation of BMF and translocation to mitochondria ⁶⁷ Activation of NOXA and translocation to mitochondria ⁶⁷ Activation of PUMA and translocation to mitochondria ⁶⁷ Activation, myristolyation of BID and translocation to mitochondria ⁶⁷ BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members ⁶⁷ Intrinsic Pathway for Apoptosis ⁶⁷	11.86	BAX BCL2 TP53
23	Sphingolipid signaling pathway ³⁸	11.84	BAX BCL2 TP53
24	Amyotrophic lateral sclerosis (ALS) ³⁸ ¹ Show member pathways Pathogenesis of ALS ⁶⁵	11.81	BAX BCL2 TP53
25	Integrated Breast Cancer Pathway ¹	11.81	BAX BCL2 TP53 VEGFA
26	Senescence and Autophagy in Cancer ¹	11.77	BCL2 PCNA TP53
27	TP53 Regulates Transcription of Cell Death Genes ⁶⁷ Show member pathways The IPAF inflammasome ⁶⁷ TP53 Regulates Transcription of Caspase Activators and Caspases ⁶⁷ TP53 Regulates Transcription of Death Receptors and Ligands ⁶⁷ TP53 Regulates Transcription of Genes Involved in Cytochrome C Release ⁶⁷ TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain ⁶⁷	11.76	BAX BCL6 TP53
28	TP53 Regulates Transcription of Cell Cycle Genes ⁶⁷ Show member pathways TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain ⁶⁷ TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest ⁶⁷ TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest ⁶⁷	11.72	BAX PCNA TP53
29	AGE-RAGE signaling pathway in diabetic complications ³⁸	11.7	BAX BCL2 VEGFA
30	Small cell lung cancer ³⁸	11.65	BAX BCL2 TP53
31	Transcription_P53 signaling pathway ²³	11.54	BCL2 TP53 VEGFA
32	Platinum drug resistance ³⁸	11.52	BAX BCL2 TP53
33	DNA Damage Response (only ATM dependent) ¹	11.52	BAX BCL2 BCL6 TP53
34	DNA damage_Role of Brca1 and Brca2 in DNA repair ²³	11.44	BCL10 PCNA TP53
35	Ceramide signaling pathway ¹	11.35	BAX BCL2
36	DNA damage_ATM/ATR regulation of G1/S checkpoint ²³	11.35	PCNA TP53
37	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.34	BAX BCL2 TP53
38	Interleukin-4 and 13 signaling ⁶⁷	11.31	BCL2 BCL6 TP53 VEGFA
39	Signaling events mediated by HDAC Class III ¹	11.29	BAX TP53
40	Integrated Cancer Pathway ¹	11.24	BAX BCL2 TP53
41	14-3-3 and Regulation of BAD Activity ⁶⁵	11.19	BAX BCL2
42	GADD45 Pathway ⁶⁵	11.19	PCNA TP53
43	BARD1 signaling events ¹	11.14	PCNA TP53
44	Direct p53 effectors ¹	11.14	BAX BCL2 BCL6 PCNA TP53
45	Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR2 ²³	11.12	BAX BCL2
46	Photodynamic therapy-induced HIF-1 survival signaling ¹	11.11	BAX TP53 VEGFA
47	Gemtuzumab ozogamicin Pathway, Pharmacokinetics/Pharmacodynamics ⁶²	11.02	BAX BCL2
48	Regulation of Apoptosis by Parathyroid Hormone-related Protein ¹	10.99	BAX BCL2
49	Overview of nanoparticle effects ¹	10.9	BAX BCL2
50	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁷	10.78	BAX BCL2 TP53

Sources

GO Terms for Gastric Lymphoma

Cellular components related to Gastric Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein-containing complex	GO:0032991	9.46	ALB BCL10 BCL2 TP53
2	replication fork	GO:0005657	8.96	BCL6 PCNA
3	pore complex	GO:0046930	8.62	BAX BCL2

Biological processes related to Gastric Lymphoma according to GeneCards Suite gene sharing:

(show all 46)

#	Name	GO ID	Score	Top Affiliating Genes
1	apoptotic process	GO:0006915	9.99	BAX BCL10 BCL2 TP53
2	negative regulation of cell proliferation	GO:0008285	9.91	BAX BCL2 BCL6 TP53
3	cell proliferation	GO:0008283	9.88	BAX BCL2 PCNA TP53
4	positive regulation of apoptotic process	GO:0043065	9.85	BAX BCL10 BCL6 TP53
5	negative regulation of apoptotic process	GO:0043066	9.85	ALB BCL2 BCL6 TP53 VEGFA
6	cytokine-mediated signaling pathway	GO:0019221	9.81	BCL2 BCL6 TP53 VEGFA
7	cellular response to hypoxia	GO:0071456	9.78	BCL2 TP53 VEGFA
8	negative regulation of cell growth	GO:0030308	9.77	BCL2 BCL6 TP53
9	kidney development	GO:0001822	9.77	BAX BCL2 VEGFA
10	cellular response to DNA damage stimulus	GO:0006974	9.77	BAX BCL2 BCL6 PCNA TP53
11	cellular response to glucose starvation	GO:0042149	9.7	BCL2 TP53
12	cellular response to organic substance	GO:0071310	9.7	BAX BCL2
13	positive regulation of B cell proliferation	GO:0030890	9.69	BCL2 BCL6
14	neuron apoptotic process	GO:0051402	9.69	BAX BCL2
15	extrinsic apoptotic signaling pathway in absence of ligand	GO:0097192	9.68	BAX BCL2
16	extrinsic apoptotic signaling pathway via death domain receptors	GO:0008625	9.68	BAX BCL2
17	intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	GO:0070059	9.68	BAX BCL2
18	negative regulation of fibroblast proliferation	GO:0048147	9.68	BAX TP53
19	homeostasis of number of cells within a tissue	GO:0048873	9.67	BAX BCL2
20	intrinsic apoptotic signaling pathway	GO:0097193	9.67	BAX TP53
21	cell aging	GO:0007569	9.67	BCL2 TP53
22	positive regulation of release of cytochrome c from mitochondria	GO:0090200	9.66	BAX TP53
23	regulation of mitochondrial membrane potential	GO:0051881	9.66	BAX BCL2
24	intrinsic apoptotic signaling pathway by p53 class mediator	GO:0072332	9.65	BAX TP53
25	negative regulation of apoptotic signaling pathway	GO:2001234	9.65	BAX BCL2
26	positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	GO:1900740	9.65	BCL2 TP53
27	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.65	BAX PCNA TP53
28	B cell homeostasis	GO:0001782	9.64	BAX BCL2
29	apoptotic mitochondrial changes	GO:0008637	9.64	BAX BCL2
30	release of cytochrome c from mitochondria	GO:0001836	9.63	BAX BCL2
31	positive regulation of protein oligomerization	GO:0032461	9.63	BAX TP53
32	endoplasmic reticulum calcium ion homeostasis	GO:0032469	9.62	BAX BCL2
33	establishment or maintenance of transmembrane electrochemical gradient	GO:0010248	9.62	ATP12A BAX
34	cellular response to UV	GO:0034644	9.61	BAX PCNA TP53
35	regulation of mitochondrial membrane permeability	GO:0046902	9.58	BCL2 TP53
36	ovarian follicle development	GO:0001541	9.58	BAX BCL2 VEGFA
37	positive regulation of cellular component movement	GO:0051272	9.57	BCL6 VEGFA
38	regulation of protein heterodimerization activity	GO:0043497	9.56	BAX BCL2
39	B cell apoptotic process	GO:0001783	9.54	BAX BCL10
40	regulation of protein homodimerization activity	GO:0043496	9.52	BAX BCL2
41	leukocyte homeostasis	GO:0001776	9.49	BAX BCL2
42	positive regulation of intrinsic apoptotic signaling pathway	GO:2001244	9.33	BAX BCL2 TP53
43	positive regulation of developmental pigmentation	GO:0048087	9.32	BAX BCL2
44	regulation of nitrogen utilization	GO:0006808	9.26	BAX BCL2
45	response to gamma radiation	GO:0010332	9.13	BAX BCL2 TP53
46	regulation of apoptotic process	GO:0042981	9.02	BAX BCL10 BCL2 BCL6 TP53

Molecular functions related to Gastric Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein heterodimerization activity	GO:0046982	9.62	BAX BCL2 TP53 VEGFA
2	channel activity	GO:0015267	9.43	BAX BCL2
3	chaperone binding	GO:0051087	9.43	ALB BAX TP53
4	histone acetyltransferase binding	GO:0035035	9.4	PCNA TP53
5	protein phosphatase 2A binding	GO:0051721	9.37	BCL2 TP53
6	protease binding	GO:0002020	9.33	BCL10 BCL2 TP53
7	identical protein binding	GO:0042802	9.23	ALB BAX BCL10 BCL2 BCL6 PCNA
8	BH3 domain binding	GO:0051434	8.96	BAX BCL2

Sources

Sources for Gastric Lymphoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia